BACKGROUND: Single-port robotic surgery is being adopted for various surgical procedures. There have been interest in and clinical use of single-port robot-assisted radical prostatectomy (spRARP), but little reported data on feasibility and early outcomes. OBJECTIVE: To describe our institution's initial experience with spRARP utilizing the da Vinci single-port (SP) robotic system. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of the initial experience of three high-volume robotic prostate surgeons performing an spRARP utilizing the da Vinci SP robotic system was carried out. SURGICAL PROCEDURE: An spRARP using the da Vinci SP robotic system was performed following the traditional retropubic or Retzius-sparing approach. MEASUREMENTS: Patient demographics, operative time, blood loss, postoperative hospital stay, complications, and catheter duration were obtained and analyzed. RESULTS AND LIMITATIONS: In a cohort of 49 patients undergoing spRARP, median age was 62yr and prostate-specific antigen 6.4. Of the patients, 35 (71%) had cT1c disease on presentation, 92% had Gleason grade group ≥2 disease, and 85% were pT2 on final pathology. Median operative time was 161min. Median blood loss was 200ml. Seven Retzius-sparing cases were performed. Four Clavien 2 complications occurred (complication rate 8.1%). Median hospital stay was 1d and median catheter duration 7d. Operative time was <200min for all three surgeons by their third case. CONCLUSIONS: The da Vinci SP system spRARP is safe and feasible, with acceptable operative time and blood loss. Further research is needed to establish noninferiority to the da Vinci Xi and Si systems, and impact of spRARP on patient-assessed cosmesis and pain. PATIENT SUMMARY: Robotic prostatectomy using a purpose-built da Vinci single-port robotic system is safe and feasible, and warrants further study to determine whether it can improve patient outcomes.
BACKGROUND: Single-port robotic surgery is being adopted for various surgical procedures. There have been interest in and clinical use of single-port robot-assisted radical prostatectomy (spRARP), but little reported data on feasibility and early outcomes. OBJECTIVE: To describe our institution's initial experience with spRARP utilizing the da Vinci single-port (SP) robotic system. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of the initial experience of three high-volume robotic prostate surgeons performing an spRARP utilizing the da Vinci SP robotic system was carried out. SURGICAL PROCEDURE: An spRARP using the da Vinci SP robotic system was performed following the traditional retropubic or Retzius-sparing approach. MEASUREMENTS: Patient demographics, operative time, blood loss, postoperative hospital stay, complications, and catheter duration were obtained and analyzed. RESULTS AND LIMITATIONS: In a cohort of 49 patients undergoing spRARP, median age was 62yr and prostate-specific antigen 6.4. Of the patients, 35 (71%) had cT1c disease on presentation, 92% had Gleason grade group ≥2 disease, and 85% were pT2 on final pathology. Median operative time was 161min. Median blood loss was 200ml. Seven Retzius-sparing cases were performed. Four Clavien 2 complications occurred (complication rate 8.1%). Median hospital stay was 1d and median catheter duration 7d. Operative time was <200min for all three surgeons by their third case. CONCLUSIONS: The da Vinci SP system spRARP is safe and feasible, with acceptable operative time and blood loss. Further research is needed to establish noninferiority to the da Vinci Xi and Si systems, and impact of spRARP on patient-assessed cosmesis and pain. PATIENT SUMMARY: Robotic prostatectomy using a purpose-built da Vinci single-port robotic system is safe and feasible, and warrants further study to determine whether it can improve patient outcomes.
Authors: Osamah Hasan; Alexandra Reed; Mohammed Shahait; Raju Chelluri; David I Lee; Ryan W Dobbs Journal: Int Urol Nephrol Date: 2022-07-29 Impact factor: 2.266
Authors: Andrew Lai; Ryan W Dobbs; Susan Talamini; Whitney R Halgrimson; Jessica O Wilson; Hari T Vigneswaran; Simone Crivellaro Journal: Transl Androl Urol Date: 2020-04